Russia has sharply increased the proportion of patients with hepatitis C receiving pangenotypic regimens

In 2019, the increased number of patients receiving treatment with modern antiviral drugs direct action without the use of interferons, their number grew by 81% compared to 2018. In addition, significantly increased the proportion of patients receiving panhematin scheme. This is evidenced by the results of a study conducted by “the Coalition of readiness for treatment.”

The annual report describes monitoring data for the procurement of drugs for the treatment of hepatitis C in Russia, the report covers the period 2019 – June 2020 as a whole to cure hepatitis C in 2019 it spent more than 6.8 billion rubles, which is 29% higher than in 2018. While 91% of the total budget was spent on the purchase of antiviral drugs direct action (DAAS). For the period from 2014 to 2019 the total budget increased 3 times, from 2.33 billion in 2014 to 6.83 billion in 2019.

The authors of the report noted the increase in the number of patients receiving modern therapy. So, in 2020, the continued growth of the share of pangenotypic schemes in the treatment programs. Note that the estimated number of patients who could be provided therapy in 2019, amounted to slightly less than 16 thousand, i.e. less than 0.5% of the total estimated number of patients with chronic hepatitis C according 2019 (3.5 million).

According to the results of the procurement 2019 and 5 months 2020 the authors of the study concluded that the approach to HCV treatment is increasingly correlated with international standards, however, treatment coverage remains extremely low. According to them, access to generic DAAS could increase access to dozens of times and at least to provide therapy to all newly diagnosed patients with HCV.

Now the average cost of treatment (June 1, 2020) is 274 thousand to 413 thousand rubles depending on the drug. The most affordable from the point of view of prices tangenterna scheme in 2020 – sofosbuvir and daclatasvir (392 thousand over the course of 12 weeks). The price of generic combination of sofosbuvir and daclatasvir in Kazakhstan – less than $ 100 over the course of 12 weeks, or about 7 thousand rubles at the current exchange rate, i.e. more than 50 times lower than in Russia.

Leave a Reply

Your email address will not be published. Required fields are marked *


Pfizer and Hikma will manufacture ramdevpir

British Hikma announced the start of production of ramdevpir of Gilead, which is currently used for the treatment of patients with COVID-19. A similar agreement for the production of antiretroviral drug Gilead has entered into with Pfizer, writes Reuters. Ramdevpir is one of two drugs that have confirmed efficacy in the treatment of coronavirus infection […]

RNC Pharma: the Russian pharmaceutical manufacturers set an absolute record

The total volume of pharmaceutical production in January-June 2020 reached 232 billion rubles, rate of growth compared to the same period 2019 to 24%, according to the RNC Pharma. Natural dynamics are somewhat more modest: 18.3% packages just for the first half of the domestic companies shipped 2.45 billion packings of medicines. The increase in […]